Our Products
Our Products

Poze

Poze

Generic:

Pioglitazone HCl

 

Therapeutic Class:

GLITAZONE A-DIABS PLAIN

 

Composition:

Poze tablet 15 mg:
Each Poze tablet contains pioglitazone hydrochloride equivalent to
pioglitazone … 15 mg

 

Poze tablet 30 mg:
Each Poze tablet contains pioglitazone hydrochloride equivalent to
pioglitazone … 30 mg

 

Poze tablet 45 mg:
Each Poze tablet contains pioglitazone hydrochloride equivalent to
pioglitazone … 45 mg

 

Description:

Poze (pioglitazone
hydrochloride) is an oral antidiabetic agent that is used in the management
of type 2 diabetes. It acts primarily by decreasing insulin resistance. It
improves sensitivity to insulin in muscle and adipose tissue and inhibits
hepatic gluconeogenesis. It reduces circulating insulin levels and improves
glycemic control.

 

Indications:

Poze is indicated for type 2
diabetes mellitus (non-insulin dependant diabetes mellitus) as an adjunct
to diet control and exercise.

Poze is recommended for monotherapy. It can also be used in combination
with sulfonylureas, metformin or insulin when diet and exercise plus the
single antidiabetic agent do not result in glycemic control.

 

Dosage:

Poze tablets can be taken once
daily with or without meals. Skipping meals, while taking Poze is not
advisable since this can lead to hypoglycemia.

 

Monotherapy:
Poze monotherapy is initiated at 15 mg or 30 mg once daily for those
patients whose diabetes is not controlled with diet and exercise.
Dose can be increased up to 45 mg once daily for those patients who do not
adequately respond to initial dose of Poze.

 

Combination therapy:
Combined therapy should be considered for those patients who do not
adequately respond to monotherapy with Poze.

Sulfonylureas:
Poze can be initiated with sulfonylureas at 15 mg to 30 mg once daily. If
the patient experiences hypoglycemia, dose of sulfonylureas should be
adjusted (decreased).

 

Metformin:
Poze can be initiated with metformin at 15 mg to 30 mg once daily. The
therapeutic effects of Poze are seen in combination with metformin in
patients regardless of dose (low or high) of metformin which the patients
are receiving.

 

Insulin:
Poze can be initiated with insulin at 15 mg to 30 mg once daily. While giving Poze in combination with insulin, dose of insulin can be decreased by 10% to 25% if the patient is hypoglycemic or if plasma glucose concentrations decrease to less than 100 mg/dl. Further adjustments should be done based on glucose-lowering response. If there is a particular risk of hypoglycemia, patients on insulin should be given 15 mg of Poze once daily initially.

 

Maximum recommended dose:
The maximum dose of Poze should not exceed 45 mg once daily.

 

Presentations:

  • Poze 15 mg is available in 14’s
  • Poze 30 mg is available in 14’s
  • Poze 45 mg is available in 14’s